Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the recommended treatment approach for oestrogen receptor (ER)-positive, HER2-negative breast cancer patients.
Prof Rugo comments on the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumour.
She also comments on the use of criteria, such as tumour grade and size, to select patients for adjuvant chemotherapy as well as the usage of immunohistochemistry (IHC) markers, such as hormone receptor markers, to identify patients for chemotherapy.
Finally, she speaks about tools, such as Adjuvant! Online and Predict, and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy.
This content is supported by Genomic Health, Inc.
